Release of tenofovir from carrageenan-based vaginal suppositories

Pharmaceutics

Volumn 6, Issue 3, 2014, Pages 366-377

  Zaveri, Toral ^a,b   Hayes, John E ^a,b   Ziegler, Gregory R ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Carrageenan; Dissolution; HIV; Microbicide; Semisoft suppository; Tenofovir

Indexed keywords

CARRAGEENAN; MICROBICIDE; POTASSIUM CHLORIDE; TENOFOVIR; WATER;

ARTICLE; BODY FLUID; CONTROLLED STUDY; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG RELEASE; GEL; IN VITRO STUDY; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; SEMEN SIMULANT FLUID; SEMISOFT VAGINAL SUPPOSITORY; SUPPOSITORY; VAGINAL SIMULANT FLUID;

EID: 84904000943     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics6030366     Document Type: Article

References (43)

1. 2012 UNAIDS World AIDS Day Report-Result. Available online: http://www.unaids.org/en/ resources/publications/2012/name,76120,en.asp (accessed on 23 January 2014).
2. Davis, K.R.; Weller, S.C. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam. Plan. Perspect. 1999, 31, 272-279.
3. Alfonsi, G.A.; Shlay, J.C. The effectiveness of condoms for the prevention of sexually transmitted diseases. Curr. Womens Health Rev. 2005, 1, 151-159.
4. Steiner, M.J.; Cates, W.; Warner, L. The real problem with male condoms is nonuse. Sex. Transm. Dis. 1999, 26, 459-462.
5. Turmen, T. Gender and HIV/AIDS. Int. J. Gynecol. Obstet. 2003, 82, 411-418.
6. Stone, A. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 2002, 1, 977-985.
7. Prejean, J.; Song, R.; Hernandez, A.; Ziebell, R.; Green, T.; Walker, F.; Lin, L.S.; An, Q.; Mermin, J.; Lansky, A. et al. Estimated HIV incidence in the united states, 2006-2009. PLoS One 2011, 6, e17502.
8. AVAC, Ongoing Clinical Trials of Topical Microbicide Candidates. Available online: https://www.k4health.org/toolkits/microbicides/ongoing-clinical-trials-topical-microbicide-candidates (accessed on 22 January 2014).
9. Abdool Karim, Q.; Abdool Karim, S.S.; Frohlich, J.A.; Grobler, A.C.; Baxter, C.; Mansoor, L.E.; Kharsany, A.B.; Sibeko, S.; Mlisana, K.P.; Omar, Z. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329, 1168-1174.
10. Bentley, M.E.; Fullem, A.M.; Tolley, E.E.; Kelly, C.W.; Jogelkar, N.; Srirak, N.; Mwafulirwa, L.; Khumalo-Sakutukwa, G.; Celentano, D.D. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am. J. Public Health 2004, 94, 1159-1164.
11. Morrow, K.; Rosen, R.; Richter, L.; Emans, A.; Forbes, A.; Day, J.; Morar, N.; Maslankowski, L.; Profy, A.T.; Kelly, C. et al. The acceptability of an investigational vaginal microbicide, pro 2000 gel, among women in a phase I clinical trial. J. Womens Health 2003, 12, 655-666.
12. Van den Berg, J.J.; Rosen, R.K.; Bregman, D.E.; Thompson, L.A.; Jensen, K.M.; Kiser, P.F.; Katz, D.F.; Buckheit, K.; Buckheit, R.W., Jr.; Morrow, K.M. "Set it and forget it": Women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav. 2014, 18, 862-870.
13. Zaveri, T.; Powell, K.A.; Li, B.; Ziegler, G.R.; Hayes, J.E. Improving Acceptability of Vaginal Drug Delivery Systems by Using Sensory Methods. In Proceedings of the Society of Sensory Professionals 3rd Technical and Professional Conference, Jersey City, NJ, USA, 10-12 October 2012.
14. Morrow, K.; Underhill, K.; Berg, J.; Vargas, S.; Rosen, R.; Katz, D. User-identified gel characteristics: A qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch. Sex. Behav. 2014, 1-9.
15. Nel, A.M.; Mitchnick, L.B.; Risha, P.; Muungo, L.T.; Norick, P.M. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among african women. J. Womens Health 2011, 20, 1207-1214.
16. Devlin, B.; Nuttall, J.; Wilder, S.; Woodsong, C.; Rosenberg, Z. Development of dapivirine vaginal ring for HIV prevention. Antivir. Res. 2013, 100, S3-S8.
17. Fetherston, S.M.; Boyd, P.; McCoy, C.F.; McBride, M.C.; Edwards, K.-L.; Ampofo, S.; Malcolm, R.K. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur. J. Pharm. Sci. 2013, 48, 406-415.
18. Pereira, L.E.; Clark, M.R.; Friend, D.R.; Garber, D.A.; McNicholl, J.M.; Hendry, R.M.; Doncel, G.F.; Smith, J.M. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob. Agents Chemother. 2014, 58, 2665-2674.
19. Cole, A.M.; Patton, D.L.; Rohan, L.C.; Cole, A.L.; Cosgrove-Sweeney, Y.; Rogers, N.A.; Ratner, D.; Sassi, A.B.; Lackman-Smith, C.; Tarwater, P. et al. The formulated microbicide rc-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One 2010, 5, e15111.
20. Akil, A.; Parniak, M.A.; Dezzuitti, C.S.; Moncla, B.J.; Cost, M.R.; Li, M.; Rohan, L.C. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv. Transl. Res. 2011, 1, 209-222.
21. Giguere, R.; Carballo-Dieguez, A.; Ventuneac, A.; Mabragana, M.; Dolezal, C.; Chen, B.A.; Kahn, J.A.; Zimet, G.D.; McGowan, I. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Cult. Health Sex. 2012, 14, 151-166.
22. Grenha, A.; Gomes, M.E.; Rodrigues, M.; Santo, V.E.; Mano, J.F.; Neves, N.M.; Reis, R.L. Development of new chitosan/carrageenan nanoparticles for drug delivery applications. J. Biomed. Mater. Res. A 2010, 92A, 1265-1272.
23. Şen, M.; Avci, E.N. Radiation synthesis of poly(n-vinyl-2-pyrrolidone)-κ-carrageenan hydrogels and their use in wound dressing applications. I. Preliminary laboratory tests. J. Biomed. Mater. Res. A 2005, 74A, 187-196.
24. Zacharopoulos, V.R.; Phillips, D.M. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin. Diagn. Lab. Immunol. 1997, 4, 465-468.
25. Buck, C.B.; Thompson, C.D.; Roberts, J.N.; Müller, M.; Lowy, D.R.; Schiller, J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006, 2, e69.
26. Skoler-Karpoff, S.; Ramjee, G.; Ahmed, K.; Altini, L.; Plagianos, M.G.; Friedland, B.; Govender, S.; de Kock, A.; Cassim, N.; Palanee, T. et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, 1977-1987.
27. González, M.E.; Alarcón, B.; Carrasco, L. Polysaccharides as antiviral agents: Antiviral activity of carrageenan. Antimicrob. Agents Chemother. 1987, 31, 1388-1393.
28. Li, B.; Zaveri, T.; Ziegler, G.R.; Hayes, J.E. User preferences in a carrageenan-based vaginal drug delivery system. PLoS One 2013, 8, e54975.
29. Li, B.; Zaveri, T.; Ziegler, G.R.; Hayes, J.E. Shape of vaginal suppositories affects willingness-to-try and preference. Antivir. Res. 2012, 97, 280-284.
30. Rohan, L.; Sassi, A. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009, 11, 78-87.
31. Godley, M.J. Quantitation of vaginal discharge in healthy volunteers. Br. J. Obstet. Gynaecol. 1985, 92, 739-742.
32. Stone, A.; Gamble, C.J. The quantity of vaginal fluid. Am. J. Obstet. Gynecol. 1959, 78, 279-281.
33. Wagner, G.; Levin, R.J. Electrolytes in vaginal fluid during the menstrual cycle of coitally active and inactive women. J. Reprod. Fertil. 1980, 60, 17-27.
34. Stone, B.A.; Alex, A.; Werlin, L.B.; Marrs, R.P. Age thresholds for changes in semen parameters in men. Fertil. Steril. 2013, 100, 952-958.
35. Lotti, F.; Corona, G.; Maseroli, E.; Rossi, M.; Silverii, A.; Degl'Innocenti, S.; Rastrelli, G.; Forti, G.; Maggi, M. Clinical implications of measuring prolactin levels in males of infertile couples. Andrology 2013, 1, 764-771.
36. Owen, D.H.; Katz, D.F. A vaginal fluid simulant. Contraception 1999, 59, 91-95.
37. Owen, D.H.; Katz, D.F. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J. Androl. 2005, 26, 459-469.
38. Wen, H.; Park, K. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice; Wiley: Hoboken, NJ, USA, 2011.
39. Mitchell, C.; Paul, K.; Agnew, K.; Gaussman, R.; Coombs, R.W.; Hitti, J. Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J. Clin. Microbiol. 2011, 49, 735-736.
40. Dusitsin, N.; Gregoire, A.T.; Johnson, W.D.; Rakoff, A.E. Histidine in human vaginal fluid. Obstet. Gynecol. 1967, 29, 125-129.
41. Preti, G.; Huggins, G.R.; Silverberg, G.D. Alterations in the organic-compounds of vaginal secretions caused by sexual arousal. Fertil. Steril. 1979, 32, 47-54.
42. Huggins, G.R.; Preti, G. Vaginal odors and secretions. Clin. Obstet. Gynecol. 1981, 24, 355-377.
43. Schwartz, J.L.; Rountree, W.; Kashuba, A.D.M.; Brache, V.; Creinin, M.D.; Poindexter, A.; Kearney, B.P. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011, 6, e25974.